mvatg17401

Vaccineexperimental

Clinical trial activity

2 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2014 (NCT02038842)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • mvatg17401

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02972450Phase 2Feb 1, 2017European Commission, FIT Biotech Ltd., French National Agency for Research on AIDS and Viral Hepatitis, Government of Switzerland, Institut National de la Santé Et de la Recherche Médicale, France, Istituto Nazionale Malattie Infettive Lazaro Spallanzani, Medical Research Council, University of Hamburg, University of Lausanne, University of London, University of Washington
NCT02038842Phase 1/Phase 2 (Phase 2)Mar 1, 2014CHU Henri Mondor, French National Agency for Research on AIDS and Viral Hepatitis
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
French National Agency for Research on AIDS and Viral HepatitisGovernment2212014
CHU Henri MondorAcademic/Hospital1012014
European CommissionGovernment1012017
FIT Biotech Ltd.For profit1012017
Government of SwitzerlandGovernment1012017
Institut National de la Santé Et de la Recherche Médicale, FranceAcademic/Hospital1012017
Istituto Nazionale Malattie Infettive Lazaro SpallanzaniAcademic/Hospital1012017
Medical Research CouncilGovernment1012017
University of HamburgAcademic/Hospital1012017
University of LausanneAcademic/Hospital1012017
University of LondonAcademic/Hospital1012017
University of WashingtonAcademic/Hospital1012017
12 organizations
Page 1 / 1